Paragonix Celebrates 100th Kidney Transplant Case with FDA-Cleared KidneyVault™ System
WALTHAM, Mass., April 21, 2025--(BUSINESS WIRE)--Paragonix Technologies, a leader in organ transplant technologies and services, today announced the successful completion of its hundredth case using the FDA-cleared KidneyVault™ Portable Renal Perfusion System. This milestone was achieved with the support of Tennessee Donor Services (TDS), an Organ Procurement Organization (OPO) that serves more than 6 million people across Tennessee and Virginia.
In recent years, the transplantation industry has removed geographic barriers to ensure organs may reach those in greatest need, meaning organs now travel farther and remain outside the body longer. For kidney transport, the gold standard of preservation is hypothermic machine perfusion - a clinically accepted therapy that continuously pumps a specialized solution through the organ. The KidneyVault System is the first hypothermic machine perfusion device specifically designed to maximize mobility. The device offers a comprehensive, portable solution from end-to-end, allowing transplant teams to continuously perfuse the kidney and monitor key perfusion metrics in real-time through a mobile-friendly, data-driven dashboard.
The innovative system was first used shortly after achieving FDA clearance in late 2024 and has been rapidly adopted by likeminded organizations across the nation ever since. Now, over 12 OPOs stock the device, and 100 donor kidneys have been placed in a KidneyVault for transplant. This rapid adoption reflects a broader shift in the field — one that embraces new technology to meet the evolving demands of organ recovery and allocation.
"Tennessee Donor Services' mission is to save and improve lives through organ, eye, and tissue donation, and we're proud of our teams who embrace innovation to save as many lives as possible. It's exciting to partner with Paragonix to be an early adopter of the KidneyVault, a technology that will help more people get their lifesaving transplant, and work alongside their teams to make donation and transplant possible," said Jill Grandas, CEO of Tennessee Donor Services.
Leading OPOs like Tennessee Donor Services are leveraging the KidneyVault System to expand access to the limited supply of donor organs and improve post-transplant outcomes. As of April 2025, nearly 90,700 people are on the kidney transplant waiting list in the U.S., representing 86% of the national transplant list. In 2024, 27,761 kidney transplants were performed, highlighting the urgent need for innovative solutions to address the organ shortage.
"This hundredth KidneyVault case is a significant milestone for Paragonix and underscores our company's commitment to enhancing the future of organ transplantation," said Dr. Lisa Anderson, President of Paragonix Technologies. "We are proud to offer advanced preservation technologies across all solid organ transplants, and our ability to provide a truly portable renal perfusion system aligns with our mission to provide 'Every Possible Advantage' to those waiting for lifesaving transplants."
For more information about Paragonix Technologies, please visit paragonix.com.
About Tennessee Donor Services
An Extraordinary Commitment to Science, Health, and Hope
Tennessee Donor Services is a non-profit, organ procurement organization (OPO) dedicated to saving and improving lives by connecting organ and tissue donations to the patients who need them. TDS serves more than six million people in Tennessee and Virginia.
About Paragonix Technologies
Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation.
A Getinge company, Paragonix Technologies provides Advanced Organ Preservation ("AOP") devices that safeguard donor organs during the journey between donor and recipient patients. Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit www.paragonix.com.
Connect with us on LinkedIn: Paragonix Technologies Follow us on Twitter: @ParagonixSherpa Like Us on Facebook: Paragonix SherpaPak
View source version on businesswire.com: https://www.businesswire.com/news/home/20250421918551/en/
Contacts
Media: Adam LafreniereVice President, Marketingmarketing@paragonixtechnologies.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
4 hours ago
- Business Insider
Sarepta says eight-year-old death deemed unrelated to Elevidys
Sarepta (SRPT) said in a statement Friday night: 'Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy patient who had received Elevidys gene therapy. The death of this patient was deemed unrelated to treatment with Elevidys…Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. Elevidys is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy.' Elevate Your Investing Strategy:
New York Post
4 hours ago
- New York Post
Breakthrough as two FDA-approved drugs are found to reverse Alzheimer's — including restoring memory
In a stunning scientific discovery, researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. And the best part of all? Both are already FDA-approved — albeit for cancer. Researchers first pinpointed how Alzheimer's disease scrambles gene activity in individual brain cells. 3 Researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. Pixel-Shot – Using the Connectivity Map database of 1,300 FDA‑approved drugs, the researchers looked for medications that reverse Alzheimer's‑associated gene expression — landing on a shortlist of five, and zeroing in on two cancer drugs. In what one researcher called a 'mock clinical trial,' they then mined 1.4 million patients' medical records, finding that those who had taken letrozole or irinotecan for cancer were significantly less likely to develop Alzheimer's. When given together in an aggressive Alzheimer's mouse model, letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Most importantly, they restored memory and learning in mice that had already developed severe symptoms. It's an exciting development for an illness that's notoriously tricky. 3 Letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Eric Hood – 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly,' Marina Sirota, the interim director of the UCSF Bakar Computational Health Sciences Institute, said in a statement. 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.' 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. 'This makes it very challenging for drug development — which traditionally produces one drug for a single gene or protein that drives disease.' 3 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. yurakrasil – The findings were published in the journal Cell. Both drugs are already FDA‑approved for other uses, which could dramatically speed up the path to human trials. However, because they are cancer drugs, repurposing them may be complex and risky. This finding adds to a growing number of potential Alzheimer's treatments. A compound found in rosemary and sage — carnosic acid — has been shown to reverse memory loss and reduce brain inflammation in mice with Alzheimer's, bringing their cognitive function back to near-normal levels. A study from Stanford Medicine found that seniors who received the shingles vaccine were 20% less likely to develop dementia over seven years. And researchers at Penn State and Stanford University discovered that a certain cancer drug could restore memory and brain function in early stage Alzheimer's models.
Wall Street Journal
6 hours ago
- Wall Street Journal
Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag
Meet Vinay Prasad, a young disciple of Bernie Sanders who ranks as one of the most powerful officials in the federal government. He determines whether patients get access to many life-saving medicines. Or not. Think of him as a one-man death panel. Dr. Prasad was named by Marty Makary, the Food and Drug Administration commissioner, as head of the agency's biologics division in May, and last month as its chief medical and scientific officer. More on why he was tapped to these posts later. But it isn't an exaggeration to say that Dr. Prasad wields more power than Anthony Fauci ever did at the National Institutes of Health.
